PGNX Progenics Pharmaceuticals Inc.

4.85
-0.01  -0%
Previous Close 4.86
Open 4.82
Price To Book 4.04
Market Cap 410031193
Shares 84,542,514
Volume 776,847
Short Ratio
Av. Daily Volume 1,316,220

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 data to be presented at AUA May 6, 2019. Phase 3 data due early 2020.
PyL
Prostate cancer
FDA approval announced July 30, 2018.
Azedra
Pheochromocytoma
Phase 3 trial met one of two co-primary endpoints.
1404
Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA)
Approved July 19 2016.
Oral RELISTOR
Chronic pain
Approved September 29, 2014.
Subcutaneous RELISTOR
Chronic pain
Abstract released at American Society of Clinical Oncology's 2014 Genitourinary Cancers Symposium Meeting in San Francisco in January 28 2014.
PSMA ADC
Cancer - metastatic castrate resistant prostate cancer (mCRPC).
Phase 2 trial to be initiated 2Q 2019.
1095
Prostate Cancer

Latest News

  1. Investor Altiva Wants to Repopulate Progenics’ Board
  2. These 3 Biotech Stocks Are Moving Closer to Profitability
  3. How Many Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Shares Did Insiders Buy, In The Last Year?
  4. Progenics Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference
  5. Progenics Pharmaceuticals Announces Presentations at the 2019 American Urological Association (AUA) Annual Meeting
  6. Edited Transcript of PGNX earnings conference call or presentation 14-Mar-19 12:30pm GMT
  7. My Post-Earnings Assessment of 2 Biotech Stocks
  8. Progenics (PGNX) Reports Q4 Loss, Misses Revenue Estimates
  9. Progenics: 4Q Earnings Snapshot
  10. The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering
  11. Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2018 Financial Results and Business Update
  12. Progenics Asserts Ownership of PSMA-617 Intellectual Property, Including Composition of Matter Patent
  13. Progenics Pharmaceuticals Announces Presentation of Safety Data for AZEDRA® (iobenguane I 131) at the 2019 Endocrine Society (ENDO) Annual Meeting
  14. Progenics Pharmaceuticals Sets Fourth Quarter and Full-Year 2018 Financial Results and Business Update Call for March 14
  15. 3 Small Biotechs to Watch as Earnings Season Winds Down
  16. Progenics Acquires AZEDRA® (iobenguane I 131) Radiopharmaceutical Manufacturing Facility
  17. Market Trends Toward New Normal in Agilent Technologies, Xilinx, Interpublic Group of Companies, Progenics Pharmaceuticals, Flexsteel Industries, and USA Truck — Emerging Consolidated Expectations, Analyst Ratings
  18. Steven Cohen Storms Into Progenics Pharmaceuticals
  19. Progenics and Curium Announce European Collaboration for Prostate Cancer Imaging Agent PyL™
  20. Progenics Pharmaceuticals Expands Leadership Team with Appointment of Asha Das, M.D. as Chief Medical Officer